Search company, investor...

Codon Devices

codondevices.com

Founded Year

2004

Stage

Dead | Dead

Total Raised

$32.5M

About Codon Devices

Codon Devices is engaged in the field of synthetic biology.

Headquarters Location

99 Erie Street Third Floor, Building 300

Cambridge, Massachusetts, 02139,

United States

617-995-7999

Missing: Codon Devices's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Codon Devices's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Codon Devices

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Codon Devices is included in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Latest Codon Devices News

Codon Devices Awarded $1.5 Million Grant by National Institute of Standards and Technology

Aug 2, 2017

10/22/07 Funding to be used for development of automated microfluidics platform for DNA assembly Cambridge, MA – October 22, 2007 – Codon Devices, Inc., the Constructive Biology Company™, today announced that it has been awarded a $1.5 million grant from the U.S. Commerce Department’s National Institute of Standards and Technology (NIST). With the support of the grant, Codon Devices will develop an integrated microfluidics platform to significantly reduce the cost and complexity of building complex DNA fragments. This platform will advance the state of the art in gene synthesis to improve the utility of synthetic biology approaches for biotechnology research. "We are thrilled that NIST has recognized Codon Devices with this ATP award,” said Brian M. Baynes, Founder and President of Codon Devices. “Funding from this initiative will enable us to develop a new generation of rapid, automated systems for construction of longer, more complex DNA sequences. By integrating this technology with our BioFAB™ Production Platform, we will make these new tools available to our customers and partners and accelerate critical applications such as drug discovery and development of renewable energy systems.” The NIST award was granted under the Agency’s Advanced Technology Program (ATP). Awarded projects were selected for funding by a competitive, peer-reviewed process that evaluated the scientific and technical merit of each proposal and the potential for broad-based benefits to the nation. NIST promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. About Codon Devices Codon Devices, Inc., based in Cambridge, MA, is a privately-held biotechnology company focused on enabling commercial applications of synthetic biology. Codon Devices' proprietary synthesis and design technologies improve the productivity of its industrial, pharmaceutical and academic customers in a paradigm shift to what the Company calls Constructive Biology™. The Company's focus is on developing and delivering high-value products and design services in a variety of application areas, including engineered gene libraries, engineered cells that produce novel pharmaceuticals, improved vaccines, agricultural products, and biorefineries for the production of industrial chemicals and energy. Codon Devices' BioFAB™ Production Platform uses sophisticated informatics, robotics and sequencing technologies to accurately synthesize genetic codes orders of magnitude more rapidly and cost-effectively than other currently available technology. More information about Codon Devices is available at www.codondevices.com . ###

Codon Devices Frequently Asked Questions (FAQ)

  • When was Codon Devices founded?

    Codon Devices was founded in 2004.

  • Where is Codon Devices's headquarters?

    Codon Devices's headquarters is located at 99 Erie Street, Cambridge.

  • What is Codon Devices's latest funding round?

    Codon Devices's latest funding round is Dead.

  • How much did Codon Devices raise?

    Codon Devices raised a total of $32.5M.

  • Who are the investors of Codon Devices?

    Investors of Codon Devices include Flagship Pioneering, Kleiner Perkins Caufield & Byers, Alloy Ventures, Tactics II Investments, Khosla Ventures and 5 more.

  • Who are Codon Devices's competitors?

    Competitors of Codon Devices include Epizyme, Promedior, Synlogic, HTG Molecular Diagnostics, Everist Health and 13 more.

Compare Codon Devices to Competitors

Everist Health Logo
Everist Health

Everist Health (formerly Everist Genomics and Genetics Squared) is a personalized medicine company which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. Through their tools, the company seeks to help physicians improve medical outcomes and reduce the total cost of care. EGI's products integrate with mobile digital services, smartphones, and tablet computers resulting in advanced medical technology.

A
Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

S
Seaside Therapeutics

Seaside Therapeutics is creating new drug treatments to correct or improve the course of Fragile X Syndrome, autism and other disorders of brain development.

A
Armgo Pharma

Armgo Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. The company's proprietary drugs, known as rycals, are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycals act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.